Key Takeaways
- Clinical Bottom Line
- Differentiating Functional from Inflammatory Diarrhea
Clinical Bottom Line
| Condition | Underlying Pathology | Alarm Symptoms (Red Flags) |
|---|---|---|
| Irritable Bowel Syndrome (IBS) | Functional disorder of motility and visceral hypersensitivity. Normal mucosa. | None. (No weight loss, bleeding, or nocturnal symptoms.) |
| Inflammatory Bowel Disease (IBD) | Destructive, immunologic ulceration of the bowel wall. | Hematochezia, anemia, nocturnal diarrhea awakening patient, severe weight loss. |
Differentiating Functional from Inflammatory Diarrhea
A central challenge in primary gastrointestinal triage is differentiating the massive volume of patients presenting with functional Irritable Bowel Syndrome (IBS-D) from those with early-stage Inflammatory Bowel Disease (IBD).
IBS is purely a disorder of gut-brain signaling, motility, and heightened pain perception. The intestinal mucosa in an IBS patient is completely normal, lacking any ulcerations, microscopic inflammation, or strictures. In contrast, IBD involves the physical immunologic destruction of mucosal tissue.
The Diagnostic Power of Fecal Calprotectin
In 2026, the reliance on vague clinical criteria (Rome IV) has been heavily augmented by Fecal Calprotectin. This neutrophil-derived protein is highly stable in stool and directly correlates to the volume of mucosal inflammation. An IBS patient experiencing severe, cramping diarrhea will have a completely normal Calprotectin level (<50 mcg/g), decisively ruling out active IBD without the immediate need for an invasive colonoscopy.
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: 2026. This article is intended for physicians.
